

## DAFTAR PUSTAKA

1. Reksodiputro A, Rudijanto A, Madjid A, Hermawan A, Rachman A, Tambunan A, et al. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Setiati S, Alwi I, Sudoyo A, Simadibrata K, Setiyohadi B, Syam A, editors. Vol. 2. Jakarta Pusat: InternaPublishing; 2014.
2. Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: Diagnosis and management. *Mayo Clin Proc.* 2019;94(4):714–26.
3. Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non-invasive assessment of portal hypertension. *Expert Rev Gastroenterol Hepatol.* 2018;12(2):155–64.
4. Zhai M, Long J, Liu S, Liu C, Li L, Yang L, et al. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. *Aging.* 2021;13(1):279–300.
5. Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJF, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. *Lancet Gastro Hepatol.* 2022;7(8):724–35.
6. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *LGH.* 2020;5(3):245–66.
7. Mathews SC, Izmailyan S, Brito FA, Yamal JM, Mikhail O, Revere FL. Prevalence and financial burden of digestive diseases in a commercially insured population. *CGHJournal.* 2022;20(7):1480-7.e7.
8. Lovena A, Miro S, Efrida E. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *JKA [Internet].* 2017;6(1):5. Available from: <http://jurnal.fk.unand.ac.id/index.php/jka/article/view/636>
9. Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. *JGE.* 2020;55(3):353–62.
10. Lange CM. Systemic inflammation in hepatorenal syndrome – A target for novel treatment strategies? *Liver Int.* 2019;39(7):1199–201.
11. Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. *Nat Rev Dis Primers.* 2018;4(1):23.
12. Relu M, Kaliamoorthy I, Rajakumar A, Appuswamy E. Renal dysfunction in cirrhosis: Critical care management. *IJCCM.* 2021;25(2):207–14.

13. Huelin P, Piano S, Solà E, Stanco M, Solé C, Moreira R, et al. Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. *CGHJournal*. 2017;15(3):438-445.e5.
14. Patidar KR, Naved MA, Grama A, Adibuzzaman M, Aziz Ali A, Slaven JE, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. *J Hepatol*. 2022;77(1):108–15.
15. Desai AP, Knapp SM, Orman ES, Ghabril MS, Nephew LD, Anderson M, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis – a US population-based study. *J Hepatol*. 2020;73(5):1092–9.
16. Khatua CR, Sahu SK, Meher D, Nath G, Singh SP. Acute kidney injury in hospitalized cirrhotic patients: Risk factors, type of kidney injury, and survival. *JGH Open*. 2021;5(2):199–206.
17. Regner KR, Singbartl K. Kidney injury in liver disease. *Crit Care Clin*. 2016;32(3):343–55.
18. Simonetto DA, Gines P, Kamath PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. *BMJ*. 2020;
19. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. *Gastroenterology*. 2011;140(2):488-496.e4.
20. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. *J Hepatol*. 2019;71(4):811–22.
21. Solé C, Pose E, Solà E, Ginès P. Hepatorenal syndrome in the era of acute kidney injury. *Liver Int*. 2018;38(11):1891–901.
22. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int*. 2021;99(3):S1–87.
23. Miller WG, Kaufman HW, Levey AS, Straseski JA, Wilhelms KW, Yu HY (Elsie), et al. National kidney foundation laboratory engagement working group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: Practical guidance for clinical laboratories. *Clin Chem*. 2022;68(4):511–20.
24. D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. *J Hepatol*. 2018;68(3):563–76.

25. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology*. 2017;65(1):310–35.
26. Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, et al. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. *World J Hepatol*. 2018;10(10):731–42.
27. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. *Hepatology*. 2019;70(6):1913–27.
28. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. *The Lancet*. 2021;398(10308):1359–76.
29. Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. *J Hepatol*. 2021;75:S49–66.
30. Micu S, Manea M, Popoiag R, Nikolic D, Andrada D, Patti A, et al. Alcoholic liver cirrhosis, more than a simple hepatic disease – A brief review of the risk factors associated with alcohol abuse. *J Mind Med Sci*. 2019;6(2):232–6.
31. Majid B, Khan R, Junaid Z, Khurshid O, Rehman SH, Jaffri SN, et al. Assessment of knowledge about the risk factors of chronic liver disease in patients admitted in civil hospital karachi. *Cureus*. 2019;
32. Fromme M, Strnad P. Pathophysiology of chronic liver disease development. *Int J Mol Sci*. 2022;23(6):3385.
33. Andy Arifputera, Chrysilla Calistania, Cindya Klarisa, Dimas Priantono, Dyah Paramita Wardhani, Elita Wibisono, et al. *Kapita Selektta Kedokteran*. 5th ed. Tanto C, Liwang F, Hanifati S, Pradipta EA, editors. Vol. 2. Depok: Media Aesculapius Fakultas Kedokteran UI; 2020.
34. Vidyani A, Vianto D, Kholili U, Maimunah U, Sugihartono T, Purbayu H, et al. Faktor risiko terkait perdarahan varises esofagus berulang pada penderita sirosis hati. *J Penyakit Dalam Indones*. 2011;12(3):169–74.
35. Dadang Makmun, Rabbinu Rangga Pribadi. *Crash Course Sistem Gastrointestinal, Hepatobilier dan Pankreas*. 4th ed. Dan Horton-Szar, editor. Singapore: Elsevier; 2015.

36. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nat Rev Gastroenterol Hepatol*. 2019;16(10):589–604.
37. Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. *J Hepatol*. 2018;69(2):406–60.
38. Kulkarni A V, Kumar P, Sharma M, Sowmya TR, Talukdar R, Rao PN, et al. Pathophysiology and prevention of paracentesis-induced circulatory dysfunction: a concise review. *J Clin Transl Hepatol*. 2020;8(10):1–7.
39. Jindal A, Kumar M, Bhadoria AS, Maiwall R, Sarin SK. Response to treatment of spontaneous bacterial peritonitis: beyond the current international guidelines. *Liver Int*. 2016;36(6):919–919.
40. Sanglodkar U, Jain M, Venkataraman J. Predictors of immediate and short-term mortality in spontaneous bacterial peritonitis. *IJG*. 2020;39(4):331–7.
41. Sanglodkar U, Jain M, Vargese J, Kedarisetty C, Venkataraman J. Clinical audit to determine efficacy of daily infusion of low dose of 20% albumin in combination with antibiotics in patients with spontaneous bacterial peritonitis. *J Clin Exp Hepatol*. 2019;5(4):301–7.
42. Amodio P. Current diagnosis and classification of hepatic encephalopathy. *J Clin Exp Hepatol*. 2018;8(4):432–7.
43. Weissenborn K. Diagnosis of minimal hepatic encephalopathy. *J Clin Exp Hepatol*. 2015;5:S54–9.
44. Ahmed S, Premkumar M, Dhiman RK, Kulkarni A V., Imran R, Duseja A, et al. Combined PEG3350 plus lactulose results in early resolution of hepatic encephalopathy and improved 28-day survival in acute-on-chronic liver failure. *J Clin Gastroenterol*. 2022;56(1):e11–9.
45. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology*. 2017;65(1):310–35.
46. Vaidya SR, Aeddula NR. Chronic Renal Failure. *The Scientific Basis of Urology, Second Edition* [Internet]. 2022 Oct 24 [cited 2023 Oct 14];257–64. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK535404/>
47. Lindell RB, Weiss SL. Shock. *Fundamentals of Pediatric Surgery, Third Edition* [Internet]. 2023 Jul 24 [cited 2023 Oct 14];101–7. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK531492/>

48. Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. StatPearls [Internet]. 2023 Jun 12 [cited 2023 Oct 14]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK559177/>
49. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 Tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019. 25 Indonesia; 2016.
50. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. *Gut*. 2015;64(4):531–7.
51. Gifford FJ, Morling JR, Fallowfield JA. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. *Aliment Pharmacol Ther*. 2017;45(5):593–603.
52. Charles C, Ferris AH. Chronic kidney disease. *Primary Care: Clinics in Office Practice*. 2020;47(4):585–95.
53. Gandhi P, Medeiros E, Shah AD. Physiology or pathology? Elevated serum creatinine in a female-to-male transgender patient. *AJKD*. 2020;75(4):A13–4.
54. Collister D, Saad N, Christie E, Ahmed S. Providing care for transgender persons with kidney disease: a narrative review. *Can J Kidney Health Dis*. 2021 20;8:205435812098537.
55. Miller WG, Bachmann LM, Delanghe JR, Inker LA, Jones GRD, Vassalotti JA. Optimal use of biomarkers for chronic kidney disease. *Clin Chem*. 2019;65(8):949–55.
56. Sujan R, Cruz-Lemini M, Altamirano J, Simonetto DA, Maiwall R, Axley P, et al. A validated score predicts acute kidney injury and survival in patients with alcoholic hepatitis. *Liver Transpl*. 2018;24(12):1655–64.
57. Makar M, Reja D, Chouthai A, Kabaria S, Patel AV. The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA. *Eur J Gastroenterol Hepatol*. 2021;33(6):905–10.
58. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. *J Hepatol*. 2019;71(4):811–22.
59. Busk TM, Bendtsen F, Møller S. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. *Expert Rev Gastroenterol Hepatol*. 2016;10(10):1153–61.

60. Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, et al. Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. *Hepatology*. 2014;60(1):250–6.
61. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. *J Hepatol*. 2014;60(1):197–209.
62. Amalia M, Hidayati PH, Yanti AKE, Vitayani S, Gayatri SW. Karakteristik pasien sirosis hepatis. *UMI Medical Journal [Internet]*. 2023 Jun 27 [cited 2024 Jan 26];8(1):53–61. Available from: <https://jurnal.fk.umi.ac.id/index.php/umimedicaljournal/article/view/244>
63. Ndraha S, Tendean M, Santoso M, Imelda. Komplikasi Penderita Sirosis Hati di RSUD Koja pada Bulan Juli-November 2017. *J Kedokt Meditek*. 2018;24(67).
64. Fida S, Murtaza S, Khurshid S, Mansoor H. Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. 2020;
65. Rubin JB, Sundaram V, Lai JC. Gender differences among patients hospitalized with cirrhosis in the United States. *J Clin Gastroenterol [Internet]*. 2020 Jan 1 [cited 2024 Jan 26];54(1):83. Available from: </pmc/articles/PMC6706332/>
66. Kamimura K, Sakamaki A, Kamimura H, Setsu T, Yokoo T, Takamura M, et al. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. *World J Gastroenterol [Internet]*. 2019 Apr 4 [cited 2024 Feb 5];25(15):1817. Available from: </pmc/articles/PMC6478616/>
67. Siregar GA, Gurning M. Renal dysfunction in liver cirrhosis and its correlation with Child-Pugh score and MELD score. *IOP Conf Ser Earth Environ Sci*. 2018;125:012214.
68. Chen YW, Wu CJ, Chang CW, Lee SY, Sun FJ, Chen HH. Renal Function in Patients with Liver Cirrhosis. *Nephron Clin Pract*. 2010;118(2):c195–203.
69. Poluan PM, Kawengian V, Sugeng C. Hubungan derajat keparahan sirosis hati dan nilai laju glomerulus pada sirosis hati. Vol. 3, *Jurnal e-Clinic (eCl)*. 2015.
70. Ahmed S, Kayesh AME, Wahiduzzaman, Mahmud M, Kibria G, Ahmed F, et al. Correlation of Serum Creatinine with Child-Pugh Score among Patients with Decompensated Cirrhosis of Liver. *Planet [Internet]*. 2023 [cited 2024 May 5];6(02):31–9. Available from: <https://bdjournals.org/index.php/planet/article/view/308>